Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron<blockquote>Vir Biotechnology在显示出对奥密克戎的中和活性后,早盘继续上涨超过7%</blockquote>
Palantir Expects 40% Revenue Growth in FY 2021; Q3 US Commercial Revenue up 103% Y/Y<blockquote>Palantir预计2021财年收入增长40%;第三季度美国商业收入同比增长103%</blockquote>